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Abstract: Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent
a novel and heterogeneous class of drugs that competitively block the potassium binding site
of gastric H+/K+ ATPase, thus potentially overcoming the limitations of proton-pump
inhibitors. Different studies evaluated the efficacy of vonoprazan versus proton-pump inhi-
bitors (PPIs) for the treatment of acid-related disorders, and, therefore, P-CABs present the
same indications of PPIs: gastroesophageal reflux disease, gastric and duodenal ulcer heal-
ing, management of upper gastrointestinal bleeding, non-steroidal anti-inflammatory drug
(NSAID)-associated ulcers and Helicobacter pylori eradication therapy. The aim of this
review was to evaluate the role of vonoprazan for the treatment of peptic ulcer disease
(PUD) and the management of gastric ulcer occurring after endoscopic submucosal dissec-
tion (ESD). Indeed, vonoprazan (at the dose of both 10 and 20mg) showed similar results to
PPIs in patients taking long-term NSAIDs, in the absence of severe adverse effects, and
provided a more rapid and effective treatment of ulcers induced by ESD. However, studies in
medical literature are heterogeneous, mainly performed with a retrospective design, and
often carried out in Japan only. For these reasons, further prospective, randomized studies are
warranted in order to help physicians, patients, and policymakers regarding the use of
vonoprazan in clinical practice.
Keywords: gastric ulcer, P-CAB, adverse events, peptic disease, PPI, H2-receptor
antagonists
Introduction
The therapeutic management of acid-related diseases and their complications have
deeply changed with the development of proton-pump inhibitors (PPIs). Since their
market release in the late 1980s, PPIs represented the mainstay for the treatment of
gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), low-dose aspirin
or non-steroidal anti-inflammatory drug-induced peptic ulcer and Helicobacter pylori
(H. pylori) infection.1–3 The first molecule introduced was omeprazole, followed by
lansoprazole, pantoprazole, rabeprazole and esomeprazole.
PPIs are prodrugs that need acid to be activated and bind covalently to the gastric
H+/K+ ATPase via disulfide bond. PPIs are metabolized and consequently inactivated
by cytochrome P450 (CYP) enzymes, mainly CYP2C19 and CYP3A4.4 Despite their
proven efficacy, PPIs present several limitations, such as delay in action onset (3–5
days), low bioavailability, nocturnal acid breakthrough, drug interactions and intake at
appropriate times relative to meals.1 Moreover, they are affected by marked inter-
individual variability of pharmacodynamics and clinical activity due to the existence of
cytochrome polymorphisms. Four distinct phenotypes were indeed described: a)
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extensive metabolizers (EM); b) intermediate metabolizers;
c) ultra-rapid metabolizers; d) poor metabolizers.4 CYP2C19
is the main responsible for the metabolism of omeprazole,
lansoprazole and pantoprazole, whereas, to note, rabeprazole
undergoes a mainly non-enzymatic metabolism with renal
elimination of its metabolites.4 Furthermore, an increasing
prevalence of antibiotic resistance associated with treatment
regimens including PPIs for the eradication of H. pylori
infection has been described.1 Finally, recently, few safety
concerns have been emphasized in different studies.5
The above considerations have stimulated the develop-
ment of novel drugs in order to overcome PPI limitations and
unmet clinical needs.1,6-8 Potassium-competitive acid block-
ers (P-CABs) represent a novel and heterogeneous class of
drugs that competitively block the potassium binding site of
gastric H+/K+ ATPase. Following their absorption into the
systemic circulation P-CABs are accumulated in the canali-
cular membrane of the parietal cells, where they are exposed
to a highly acidic environment and promptly protonated. In
contrast to PPIs, P-CABs are acid-stable and do not require
enteric-coated formulations. Furthermore, P-CABs show
a faster onset of acid inhibition and intragastric pH elevation
than PPIs due to their ability of quickly achieving peak
plasma levels after oral administration and consequently
they block H+/K+ ATPase without requiring proton-pump
activation.1 Thanks to these features, P-CABs are able to
reach a full antisecretory effect since the first dose assump-
tion and to offer a more stable control of gastric pH than PPIs.
The first P-CAB used in clinical practice was revapra-
zan, available in South Korea and India since 2007.4
Recently Takeda Pharmaceutical Company Limited
(Japan) developed a novel and innovative P-CAB called
vonoprazan, which is characterized by a potent, rapid and
long-lasting effect, thanks to a reversible inhibition of
gastric proton pump by a competitive block of the potas-
sium binding site on the luminal surface of H+/K+
ATPase.1 Vonoprazan is a weak base, with a higher value
of alkaline pKa (>9) than previous P-CABs and PPIs and,
when exposed to acid, undergoes an instant protonation
and accumulate at high concentrations in the canaliculi of
parietal cells, thus determining higher stability in an acidic
environment than PPIs.1,4 Vonoprazan is highly selective
for binding to H+/K+ ATPase and is able to perform
a powerful block of the gastric proton pump even in
neutral conditions.1 Furthermore, Vonoprazan dissociates
from the proton pump slower than other P-CABs resulting
in a longer duration of antisecretory effect.
Preclinical studies, both in vitro and in vivo, showed that
the metabolism of vonoprazan is due to multiple hepatic
metabolic enzymes.1 In contrast to PPIs, vonoprazan metabo-
lism has a limited influence by CYP polymorphisms and is
metabolized to its inactive form mainly by CYP3A4.4 Due to
its rapid, strong and continuous gastric acid suppression, vono-
prazan has been approved in Japan for the treatment of acid-
related diseases.
There are different studies that evaluate the efficacy of
vonoprazan versus PPIs. In fact, this drug has the same
indications of PPIs: gastroesophageal reflux disease, gas-
tric and duodenal ulcers healing, management of upper
gastrointestinal bleeding, non-steroidal anti-inflammatory
drugs (NSAIDs)-associated ulcers and H. pylori eradica-
tion therapy. The aim of this review is to evaluate the role
of vonoprazan for the treatment of gastric ulcers through
a deep revision of the literature.
Vonoprazan Therapy in Peptic Ulcer
Disease
PUD is a chronic acid-related disease that usually occurs in the
stomach or duodenum and is a common cause of gastrointest-
inal bleeding. The two main risk factors for PUD areH. pylori
infection and the use of NSAIDs in patients at high risk. In the
last decades of the twentieth century, the incidence of PUD
began to decrease following two important developments: the
synthesis of effective and potent acid suppressants such as
PPIs and the discovery of H. pylori. However, despite the
increasing recognition and eradication of H. pylori, it still
affects up to 20% of adult population in Asia. As to the use
of NSAIDs and/or aspirin, in the last decades, wewitnessed an
increase of their administration, particularly in the elderly
population, due to the rising incidence of cardiovascular dis-
eases and rheumatic disorders. To note, despite the use of
NSAIDs and/or aspirin represents one of themajor risk factors
for upper gastrointestinal bleeding, discontinuing these thera-
pies is often difficult (i.e. chronic pain, cardiovascular risk),
and this requires the adoption of some measures to prevent
a possible bleeding.
Due to its pharmacodynamic and pharmacokinetic
advantages compared to PPIs, vonoprazan has been eval-
uated for the treatment of gastric ulcers. A randomized
trial confirmed the non-inferiority of vonoprazan com-
pared to lansoprazole in the treatment of gastric ulcer
(93.5% and 93.8%, respectively), even if there was
a possible bias due to the fact that drop-out subjects
were put in the non-healed group. In this double-dummy
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blind study, Miwa et al enrolled patients over the age of 20
years with at least one endoscopically confirmed gastric or
duodenal ulcer and randomized them to receive lansopra-
zole (30 mg) or vonoprazan (20 mg) for 8 weeks.9
Other studies with vonoprazan (at the dose of both 10
and 20mg) showed similar results to PPIs in patients tak-
ing long-term NSAIDs, in the absence of severe adverse
effects. Therefore, vonoprazan at the dose of 10mg has
been approved for this indication.10,11
Management of Gastric Ulcer Occurring
After Endoscopic Submucosal Dissection
The endoscopic treatment of pre-neoplastic or early-stage
lesions of the digestive tract has evolved in the last 20
years. Indeed, nowadays we have a complex technique that
allows us to remove the lesion en-bloc and reaches the
muscular layer. This technique, called Endoscopic
Submucosal Dissection (ESD), is based on the use of
dedicated needles that, by cutting into the mucosa and
submucosa, permit a radical “surgical” resection of lesions
and a precise histological diagnosis.12–15
Nowadays, ESD is a very effective tool for endoscopic
treatment of neoplasms located in the mucosa, but is complex
and conceptually approaches surgical resection resulting in
potential complications.13 The main adverse events associated
with ESD are represented by bleeding, perforation and pain.
Bleeding is the most frequent event and occurs in a percentage
of cases ranging from 5% to 8%. It is more frequent for gastric
lesions than for the colon ones and the upper third of the
stomach is more at risk of bleeding than the distal body and
antrum. During the procedure, minor bleeds are very frequent
and depend on the cut of submucosal vessels, while late
bleeding (>72 hours) is usually rarer, smaller and tends to
limit itself without the need for endoscopic therapies.
Normally gastric ulcers induced by ESD heal within 8
weeks, but it is necessary to consider size, location, infection
with H. pylori, and extent of gastric atrophy.16,17
PPIs are commonly prescribed in order to prevent bleeding
and promote healing of gastric ulcers induced by ESD proce-
dure. However, the most effective therapy for this condition
remains controversial, because the data derived from
literature are conflicting (Table 1). Ichida et al18 performed
a randomized controlled trial to evaluate the effects of vono-
prazan plus rebamipide versus esomeprazole plus rebamipide
on gastric ulcer healing induced by ESD. They demonstrated
that there was no significant difference between the two drug
combinations, but the delayed bleeding rate was lower in the
vonoprazan plus rebamipide group, even though the statistical
significance was not reached. In another prospective rando-
mized study, Hamada et al19 assessed the efficacy of vonopra-
zan versus lansoprazole in preventing delayed bleeding after
gastric ESD. The bleeding rate in the vonoprazan group was
significantly lower than the threshold rate, while this was not
the same in the PPI group. Therefore, vonoprazanwas found to
be effective in preventing delayed bleeding even though the
difference between the two drugs was small. In this Phase III
Table 1 Summary of Papers, Reviews and Meta-Analysis Included in This Paragraph
Country Study Design Dose of
Vonoprazan
Comparator (PPIs) Number of Patients Included
(Vonoprazan/PPIs)
Ichida et al 201918 Japan Prospective 20 mg Esomeprazole 84 (44/40)
Hamada et al 201919 Japan Prospective 20 mg Lansoprazole 139 (69/70)
Komori et al 201920 Japan Prospective 20 mg Rabeprazole 40 (20/20)
Kakushima et al
201921
Japan Retrospective 20 mg Rabeprazole/Lansoprazole/
Esomeprazole
130 (59/71)
Kim et al 201922 Japan Systematic review-
meta analysis





10 mg/20 mg Lansoprazole/Omeprazole 461 (215/246)
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study, a sub-analysis suggested that vonoprazan could reduce
the incidence of bleeding in a particular class of patients, that is
those with lesions larger than 2 cm or with an ulcer or scar
located in the antrum. Komori et al20 compared the efficacy of
rabeprazole and P-CABs in the treatment of post-ESD gastric
ulcers. At 4 weeks after the procedure, ulcer healing rate was
significantly higher in the rabeprazole group, but this study
presented some limitations including the small sample size, the
short duration of protocol, and the fact that CYP2C19 poly-
morphisms were not investigated. Kakushima et al21 com-
pared the incidence of delayed bleeding after ESD between
vonoprazan and various PPIs in patients who did not stop the
assumption of antithrombotic drugs before the endoscopic
procedure. Antithrombotic agents included either antiplatelet
drugs (low-dose aspirin, cilostazol, etc.) and anticoagulants
(warfarin or direct oral anticoagulant). This study was retro-
spective and evaluated a single-center experience, the sample
size was small and PPIs were multiple, but also with these
limitations the occurrence of delayed bleeding was not mark-
edly different between the two groups and was higher among
patients undergoing ESD during continuous antithrombotic
treatment.
In medical literature, there are also systematic reviews and
meta-analyses that evaluated the various articles currently
present about the role of vonoprazan in the management of
post-ESD gastric ulcers. Kim et al22 published a network
meta-analysis of all relevant controlled trials published from
2005 to October 2017 in order to compare the efficacy of
various anti-ulcer medications after ESD. The primary end-
point was the efficacy of anti-ulcer drugs at 4 weeks and the
secondary at 8 weeks post-ESD. Twenty-one RCTs were
included with 2005 patients. At 4 weeks after ESD, the com-
bination of PPI plusmuco-protective agent was superior to PPI
alone and vonoprazan, but vonoprazan resulted to be the most
effective therapy at 8 weeks. The authors concluded that
a first-line therapy with a combination of PPI plus muco-
protective agent should be preferred, since it is probably
more important to achieve a rapid healing of the iatrogenic
ulcer due to the fact that the majority of bleeding episodes
occur in the early phases after the procedure. However, this
meta-analysis presented some limitations: the efficacy of
vonoprazan was evaluated in 3 studies with small sample
size and therefore the quality of evidence was rated as low
or very low, various PPIs were used, there were no publica-
tions with languages other than English, and the superiority of
vonoprazan at 8 weeks should be interpreted with caution.
Another systematic review and meta-analysis using
Medline and Embase databases23 evaluated comparative
studies assessing the rate of complete healing and delayed
bleeding of ulcers caused by ESD in patients who received
vonoprazan versus PPIs. It considered only six retrospective
and observational studies with a total amount of 461 patients
and showed a significantly higher healing rate at 4–8 weeks
after ESD in the vonoprazan group than in the PPI group,
although the statistical significance was not reached.
Furthermore, a more recent systematic review and meta-
analysis,24 that included seven published randomized clinical
trials with a total amount of 548 patients, compared the use of
vonoprazan and PPIs for the treatment of peptic ulcers result-
ing from ESD and considered the ulcer healing rate, the drug
safety and the occurrence of unwanted events, such as perfora-
tion, delayed bleeding and hepatic injury between the two
groups. The results showed no significant difference in the
healing rate between the groups with a marginal superiority of
PPIs. In terms of safety, this study showed fewer adverse
events in the vonoprazan group but without statistical rele-
vance. Finally, Kang et al25 performed a systematic review and
meta-analysis with the aim of comparing vonoprazan and PPIs
in the treatment of ESD-induced ulcers and the prevention of
delayed bleeding in randomized controlled trials and cohort
studies. They did not observe significant differences between
the two drugs in shrinkage rate (two studies, including 1 RCT
and 1 cohort study) and in delayed bleeding (11 studies,
including 6 RCTs and 5 cohort studies) at 4 weeks post-ESD.
There was also no evidence of significant difference in ulcer
size at week 0 (9 studies including 5 RCTs and 4 cohort
studies) and at week 8 post-ESD (3 studies, including 2
RCTs and 1 cohort study), but, in contrast, ulcer size reduction
at 4 weeks post-ESD was significantly higher in the vonopra-
zan group (4 RCTs). However, it has been shown a superiority
of vonoprazan in ulcer healing rate in the early phase of the
healing process. Indeed, vonoprazan offered a more rapid and
effective treatment of artificial ulcers after ESD than PPIs. To
note, this review included 1265 patients from 12 studies, but
presented some limitations because the studies were hetero-
geneous, some evidences come from retrospective studies and
all trials came from Japan.
In order to overtake the limitations of these reviews and in
order to help physicians, patients, and policymakers regarding
the use of vonoprazan in ESD-induced ulcers, Martin et al26
have proposed a specific protocol for meta-analysis of rando-
mized controlled trials and observational studies with the aim
of assessing whether vonoprazan has better efficacy than PPIs
for treating ESD-induced ulcers and preventing delayed bleed-
ing at different lengths of treatment periods (2, 4 and 8weeks).
They included thirteen studies with follow-up at least longer
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than 2 weeks, with measurements of shrinkage rate of post-
ESD ulcers and with adequate number of people in ESD-
induced scar stage and people with delayed bleeding. The
researchers showed that vonoprazan was more effective than
PPIs for treatingH. pylori-positive patients with ESD-induced
gastric ulcers during the first two weeks of treatment.27
Conclusions
Current data show that vonoprazan (at the dose of both 10
and 20mg) for the treatment of PUD is as effective as PPIs
in patients taking long-term NSAIDs, in the absence of
severe adverse effects. Moreover, vonoprazan offers
a more rapid and effective treatment of artificial ulcers
after ESD and is more effective than PPIs for treating
H. pylori-positive patients with ESD-induced gastric
ulcers during the first 2 weeks of treatment. However,
available studies in medical literature are heterogeneous,
mainly performed with a retrospective design, and often
carried out in Japan only. For these reasons, further pro-
spective, randomized studies are warranted in order to help
physicians, patients, and policymakers regarding the use of
vonoprazan in daily clinical practice.
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